ES2104635T3 - Nuevo peptido porcino con una actividad fisiologica (cnp-53). - Google Patents

Nuevo peptido porcino con una actividad fisiologica (cnp-53).

Info

Publication number
ES2104635T3
ES2104635T3 ES91111629T ES91111629T ES2104635T3 ES 2104635 T3 ES2104635 T3 ES 2104635T3 ES 91111629 T ES91111629 T ES 91111629T ES 91111629 T ES91111629 T ES 91111629T ES 2104635 T3 ES2104635 T3 ES 2104635T3
Authority
ES
Spain
Prior art keywords
cnp
physiological activity
new porcine
porcine peptide
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91111629T
Other languages
English (en)
Inventor
Hisayuki Matsuo
Kenji Kangawa
Naoto Minamino
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of ES2104635T3 publication Critical patent/ES2104635T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/58Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE DESCRIBE UN PEPTIDO COMPUESTO DE 53 RESIDUOS DE AMINO ACIDO REPRESENTADO POR LA SIGUIENTE SECUENCIA DE AMINO ACIDO: Y SUS DERIVADOS REPRESENTADOS POR LA SIGUIENTE SECUENCIA DE AMINO ACIDO: DONDE X ES COMO SE MUESTRA EN LA ESPECIFICACION. ESTOS POLIPEPTIDOS SON NUEVOS Y TIENEN ACCIONES NATRIURETICAS E HIPOTENSORAS.
ES91111629T 1990-07-13 1991-07-12 Nuevo peptido porcino con una actividad fisiologica (cnp-53). Expired - Lifetime ES2104635T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2186582A JP2930380B2 (ja) 1990-07-13 1990-07-13 ブタ由来新規生理活性ペプチド(cnp―53)

Publications (1)

Publication Number Publication Date
ES2104635T3 true ES2104635T3 (es) 1997-10-16

Family

ID=16191066

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91111629T Expired - Lifetime ES2104635T3 (es) 1990-07-13 1991-07-12 Nuevo peptido porcino con una actividad fisiologica (cnp-53).

Country Status (8)

Country Link
US (1) US5340920A (es)
EP (1) EP0466174B1 (es)
JP (1) JP2930380B2 (es)
AT (1) ATE154641T1 (es)
DE (1) DE69126568T2 (es)
DK (1) DK0466174T3 (es)
ES (1) ES2104635T3 (es)
GR (1) GR3024581T3 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100691545B1 (ko) 1998-09-28 2007-03-09 산텐 세이야꾸 가부시키가이샤 나트륨 이뇨 펩티드를 유효 성분으로하는 누액 분비 촉진또는 각결막 장해 치료용 점안제
BRPI0203172B8 (pt) 2001-09-28 2021-05-25 Nakao Kazuwa composição farmacêutica para acondroplasia
CN1960758B (zh) * 2004-03-31 2014-10-22 中外制药株式会社 关节炎的治疗剂或预防剂
EP1743653A4 (en) 2004-03-31 2009-09-30 Kazuwa Nakao COMPOSITION FOR INCREASING BODY SIZE
EP1759001B1 (en) 2004-04-21 2011-04-13 Enobia Pharma Inc. Bone delivery conjugates and method of using same to target proteins to bone
JP2011504506A (ja) 2007-11-21 2011-02-10 バイオマリン ファーマシューティカル インコーポレイテッド C型ナトリウム利尿ペプチドの変異体
KR102225470B1 (ko) 2009-05-20 2021-03-10 바이오마린 파머수티컬 인크. 씨형 나트륨이뇨 펩티드의 변이체
CA2823066A1 (en) 2010-12-27 2012-07-05 Alexion Pharma International Sarl Compositions comprising natriuretic peptides and methods of use thereof
CA2852874A1 (en) 2011-10-19 2013-04-25 Alexion Pharma Holding Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
US10822596B2 (en) 2014-07-11 2020-11-03 Alexion Pharmaceuticals, Inc. Compositions and methods for treating craniosynostosis
MX2017007392A (es) 2014-12-05 2019-01-24 Alexion Pharma Inc Tratamiento de convulsiones con fosfatasa alcalina recombinante.
JP6868561B2 (ja) 2015-01-28 2021-05-12 アレクシオン ファーマシューティカルズ, インコーポレイテッド アルカリホスファターゼ欠損を有する被験者を治療する方法
AU2016308624B2 (en) 2015-08-17 2022-06-23 Alexion Pharmaceuticals, Inc. Manufacturing of alkaline phosphatases
JP6868617B2 (ja) 2015-09-28 2021-05-12 アレクシオン ファーマシューティカルズ, インコーポレイテッド 低ホスファターゼ血症の組織非特異的アルカリホスファターゼ(tnsalp)酵素補充療法に有効な投薬計画の特定
EP3368062A4 (en) 2015-10-30 2019-07-03 Alexion Pharmaceuticals, Inc. METHODS OF TREATING CRANIOSYNOSTOSIS IN A PATIENT
US11065306B2 (en) 2016-03-08 2021-07-20 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
EP3436052A4 (en) 2016-04-01 2019-10-09 Alexion Pharmaceuticals, Inc. TREATMENT OF MUSCLE WEAKNESS USING ALKALINE PHOSPHATASES
EP3436020A4 (en) 2016-04-01 2019-12-25 Alexion Pharmaceuticals, Inc. METHOD FOR TREATING HYPOPHOSPHATASIE IN TEENS AND ADULTS
US10988744B2 (en) 2016-06-06 2021-04-27 Alexion Pharmaceuticals, Inc. Method of producing alkaline phosphatase
US11116821B2 (en) 2016-08-18 2021-09-14 Alexion Pharmaceuticals, Inc. Methods for treating tracheobronchomalacia
EP3600383A4 (en) 2017-03-31 2020-10-28 Alexion Pharmaceuticals, Inc. METHODS FOR TREATMENT OF HYPOPHOSPHATASIA (HPP) IN ADULTS AND ADOLESCENTS
EP3773684A1 (en) 2018-03-30 2021-02-17 Alexion Pharmaceuticals, Inc. Manufacturing of glycoproteins
EP4291224A1 (en) 2021-02-12 2023-12-20 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2544929B2 (ja) * 1987-06-17 1996-10-16 第一化学薬品 株式会社 新規生理活性ペプチド
US5114923A (en) * 1988-05-31 1992-05-19 California Biotechnology Inc. Recombinant techniques for production of novel natriuretic and vasodilator peptides

Also Published As

Publication number Publication date
GR3024581T3 (en) 1997-12-31
DK0466174T3 (da) 1998-01-12
DE69126568T2 (de) 1997-11-27
JP2930380B2 (ja) 1999-08-03
US5340920A (en) 1994-08-23
EP0466174B1 (en) 1997-06-18
JPH0474198A (ja) 1992-03-09
EP0466174A1 (en) 1992-01-15
DE69126568D1 (de) 1997-07-24
ATE154641T1 (de) 1997-07-15

Similar Documents

Publication Publication Date Title
ES2104635T3 (es) Nuevo peptido porcino con una actividad fisiologica (cnp-53).
DK81685A (da) Biologisk aktivt peptid og terapeutisk middel indeholdende et saadant peptid
FI894187A0 (fi) Pulmonar ytaktivt protein och polypeptid anslutande daertill.
ATE154387T1 (de) Cdna für ratten c-typ natriuretisches peptid und vorläuferprotein
DK0466175T3 (da) Porcint CNP-gen og præcursor-protein
DK193887A (da) Peptid med bronchodilartorisk og hypotensiv aktivitet
NO971621L (no) Keratinocyttvekstfaktoranaloger
SE7712634L (sv) Ny polypeptid med serumkalciumreducerande aktivitet
SE8702520D0 (sv) Mammal intestine hormone precursor
DK0490383T3 (da) Peptider af HIV-gag-proteinet, fremstilling og anvendelse deraf
AU2254588A (en) Biologically active segments of several growth hormones
DK0475842T3 (da) Ekspressionskassette for et forstadium af endothiapepsin i Cryphonectria parasitica
ES2066964T3 (es) Una proteina reg.
ATE75486T1 (de) Anorexigenische und hypotensive peptide.
SE9603461D0 (sv) New compounds
ITFI920071A1 (it) Antigeni ricombinanti proteici ad aumentata immunogenicita' contenenti il peptide rappresentato dalla sequenza vqgeesndk
ATE416781T1 (de) Antigene modifikation von polypeptiden
DK198990D0 (da) Biologisk aktivt polypeptid og fremgangsmaade til omdannelse af dette til et modent protein
DK53290A (da) Syntetiske gaer-leader-peptider
EP0266006A3 (en) Novel hypotensive diuretic peptides

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 466174

Country of ref document: ES